newsfilter
← Earnings
Earnings Releases·

Autolus Therapeutics — Third Quarter 2026 Earnings Summary

Autolus Therapeutics reported net product revenue of $41.2 million for the third quarter of 2026, representing a 95% year-over-year increase driven by AUCATZYL sales. The company raised its full-year 2026 revenue guidance to at least $150 million and achieved a gross margin of 57% through manufacturing efficiency and increased volumes. Clinical programs for obe-cel are advancing in pediatric ALL, lupus nephritis, and progressive multiple sclerosis, with the FDA granting RMAT designation for lupus indications in September 2026.

Company
AUTOLUS THERAPEUTICS PLC
Sector
Healthcare
Industry
Biotechnology